Key statistics
On Friday, Halozyme Therapeutics Inc (HALO:NSQ) closed at 59.24, -9.60% below its 52-week high of 65.53, set on Aug 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 59.83 |
---|---|
High | 59.83 |
Low | 58.71 |
Bid | 59.25 |
Offer | 61.20 |
Previous close | 59.50 |
Average volume | 1.31m |
---|---|
Shares outstanding | 126.68m |
Free float | 125.31m |
P/E (TTM) | 22.97 |
Market cap | 7.50bn USD |
EPS (TTM) | 2.58 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
- Halozyme to Present at Upcoming Investor Conferences
- HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Halozyme to Report Second Quarter 2024 Financial and Operating Results
- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
More ▼